Protein & cell
Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching.
Liu Chaohua, Xu Fei, Wu Yutuan, Li Jiana, Ni Mengdong, Xia Siyu, Chen Lihua, Zhao Haiyun, Yu Min, Zhou Yuqi, Zhang Meiqin, Li Jiajia, Wu Xiaohua, Huang Yan, Zhu Tao
Published: 202510.1093/procel/pwaf091
Abstract
Epithelial ovarian cancer (EOC) is an aggressive malignancy with limited therapeutic options. Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown remarkable efficacy, especially in BRCA-mutant patients, and are approved as maintenance therapy t…
Preview only. Read the full abstract at the source